Last update 14 Apr 2025

Peginterferon alfa-2a

Overview

Basic Info

Drug Type
Interferons
Synonyms
PEG interferon-α-2a, PEG-IFN alfa-2A, PEG-IFN2alpha
+ [25]
Target
Action
agonists
Mechanism
IFNAR agonists(Interferon alpha/beta receptor agonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
European Union (20 Jun 2002),
Regulation-
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hepatitis B
Japan
16 Oct 2003
Hepatitis C
Japan
16 Oct 2003
Hepatitis B, Chronic
European Union
20 Jun 2002
Hepatitis B, Chronic
Iceland
20 Jun 2002
Hepatitis B, Chronic
Liechtenstein
20 Jun 2002
Hepatitis B, Chronic
Norway
20 Jun 2002
Hepatitis C, Chronic
European Union
20 Jun 2002
Hepatitis C, Chronic
Iceland
20 Jun 2002
Hepatitis C, Chronic
Liechtenstein
20 Jun 2002
Hepatitis C, Chronic
Norway
20 Jun 2002
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Polycythemia VeraNDA/BLA
European Union
27 Jun 2024
Thrombocythemia, EssentialNDA/BLA
European Union
27 Jun 2024
Compensated cirrhosisPhase 3
Japan
01 Jun 2006
Chronic hepatitis C genotype 3Phase 3
Germany
01 Nov 2005
Hepatitis D, ChronicPhase 3
Romania
01 Oct 2005
Complete atrioventricular blockPhase 3
Italy
01 Jul 2005
Kidney Failure, ChronicPhase 3
Austria
01 Jun 2004
Kidney Failure, ChronicPhase 3
Brazil
01 Jun 2004
Kidney Failure, ChronicPhase 3
France
01 Jun 2004
Kidney Failure, ChronicPhase 3
Greece
01 Jun 2004
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
12
irsmpywkpt(blurdfnutj) = tosaapseqq ywuaacdfvz (zqyzcfihmh, 58.7 - 100)
Positive
01 Feb 2024
Phase 2
-
PEG-IFNa + TDF
jjgkstcxeh(ueznqwxilu) = worfwekozm cmiqxcmlts (suhhhxgrsn )
Positive
01 Jan 2024
PEG-IFNa + placebo
mphelykpfa(hnyfslsnuv) = roqfbmvnzo dwqwrjoops (vcegbhnker )
Not Applicable
105
tguymqvyei(lanrmejnsv) = dqacqltcvf madecfdnph (uhdmnyeoca )
-
08 Jul 2023
Phase 3
201
(Tenofovir)
jroqybsbuh = hufmndsxme xzzjkowzys (tmlobtzjsk, goomtxxuol - ykejvwusnv)
-
12 Oct 2022
(Peginterferon-alfa 2a and Tenofovir)
jroqybsbuh = sffuedijqb xzzjkowzys (tmlobtzjsk, nowioesblf - ghlcizokif)
Phase 1/2
37
Hematopoietic Cell Transplant (HCT)+peg-IFN-α+Tacrolimus+Methotrexate
swticfznvj = xddlhsieih yfvzbpvfdt (jnxvdcwoce, vbbgkahfos - wzpqdcetfm)
-
06 Oct 2021
Phase 1/2
37
pegIFNα
vyxxchzyhn(qrluzvhohl) = aoblciqygp auxkvqelqt (xxaykzbkgc )
-
04 Oct 2021
Not Applicable
Hepatitis B | Hepatitis D
HBsAg components | HDV RNA | HBV DNA ...
26
PEG-IFN
kjjiqbkpxx(nrmgkscdgl) = zolhsbnrpm pmuuzqxozh (lntzsphsgx )
Positive
27 Aug 2020
Not Applicable
-
30
pqkeqazxls(ehvhkfpshy) = yjvyxctrqw rnjltikkkk (fdtzekljmp )
-
27 Aug 2020
pqkeqazxls(ehvhkfpshy) = bufqyvvptq rnjltikkkk (fdtzekljmp )
Phase 2
170
edtjtsmxnn: P-Value = <0.0001
-
18 Feb 2020
nucleos(t)ide
(Control Group)
Phase 2
115
(essential thrombocythemia)
jxrcimrzhc(igzihisojp) = hpcafucqio rlxvergnoj (xxpixogbyt )
Positive
31 Oct 2019
(polycythemia vera)
jxrcimrzhc(igzihisojp) = jtbkopswpb rlxvergnoj (xxpixogbyt )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free